NEW YORK, March 21, 2017 /PRNewswire/ --
Stock-Callers.com shifts focus on the Services sector, which, though classified as the third economic sector, is responsible for the largest portion of the economy's business activity. Equities under review this morning within this space are: H&R Block Inc. (NYSE: HRB), VCA Inc. (NASDAQ: WOOF), Myriad Genetics Inc. (NASDAQ: MYGN), and QIAGEN N.V. (NASDAQ: QGEN). Learn more about these stocks by accessing their free research reports at:
Kansas City, Missouri headquartered H&R Block Inc.'s shares saw a drop of 2.37%, finishing Monday's trading session at $23.87. A total volume of 4.70 million shares was traded, which was higher than their three months average volume of 3.12 million shares. In the last month and the previous three months, the stock has advanced 17.20% and 4.36%, respectively. Additionally, the Company's shares have gained 4.82% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.45% and 6.58%, respectively. Moreover, shares of H&R Block, which through its subsidiaries, provides tax preparation and other services to the general public primarily in the US, Canada, and Australia, have a Relative Strength Index (RSI) of 64.25.
On March 07th, 2017, H&R Block announced that during Q3 FY17 revenues decreased $22.7 million to $451.9 million, due to the delayed tax season, while total operating expenses declined $18 million primarily due to cost reduction efforts, which led to lower compensation and benefits and marketing costs. The Company's loss per share increased by $0.15 due entirely to reductions in H&R Block's effective tax rate and shares outstanding. Free research report on HRB is available at:
On Monday, shares in Los Angeles, California headquartered VCA Inc. recorded a trading volume of 380,603 shares, and ended the session 0.07% higher at $91.49. The stock has gained 0.79% in the last one month, 39.59% over the previous three months, and 33.27% on an YTD basis. The Company's shares are trading 1.53% above their 50-day moving average and 25.18% above their 200-day moving average. Furthermore, shares of VCA Inc., which operates as an animal healthcare company in the US and Canada, have an RSI of 69.10.
On March 15th, 2017, VCA Animal Hospitals announced that it has piloted the use of 3D printing for a veterinary prosthetic for an amputee parrot. Dennis Keith, DVM, DACVR, medical director and radiologist at VCA Animal Referral and Emergency Center of Arizona, was contacted by a colleague from a nearby avian practice about Bandit, a 25-year-old parrot who had lost a part of his leg when it became stuck in his cage. Dr. Keith had the idea to use the center's 3D printer to model a prosthetic leg for Bandit. The complimentary research report on WOOF can be downloaded at:
Shares in Salt Lake City, Utah headquartered Myriad Genetics Inc. closed flat at $19.05. The stock recorded a trading volume of 721,183 shares. The Company's shares have gained 10.31% in the last one month, 5.95% over the previous three months, and 14.28% since the start of this year. The stock is trading 9.17% above its 50-day moving average. Additionally, shares of Myriad Genetics, which focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide, have an RSI of 60.13.
On March 13th, 2017, Myriad Genetics announced that it has launched the EndoPredict® test in the US for patients with ER+ HER2- early-stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy. Visit us today and access our complete research report on MYGN at:
Venlo, the Netherlands headquartered QIAGEN N.V.'s stock ended 0.65% lower at $29.19 with a total trading volume of 513,010 shares. The Company's shares have advanced 1.71% in the last one month, 5.20% over the previous three months, and 4.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.34% and 10.51%, respectively. Furthermore, shares of QIAGEN, which provides sample to insight solutions that transform biological materials into valuable molecular insights worldwide, have an RSI of 51.05.
On February 16th, 2017, QIAGEN announced that data published in The Lancet Respiratory Medicine journal shows screening with QuantiFERON-TB Gold can detect latent tuberculosis (TB) infection in otherwise healthy young children and can predict which are likely to progress to the active stage of this life-threatening respiratory disease. Results from the study of more than 2,500 young children in South Africa suggest that screening with the modern QuantiFERON-TB blood test could save lives in countries with a high TB burden by identifying those children most at risk of developing active disease. Get free access to your research report on QGEN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA